These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17363751)

  • 1. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).
    ; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
    Diabetes Care; 2007 Jun; 30(6):1581-3. PubMed ID: 17363751
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
    ; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
    Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Shiga Microalbuminuria Reduction Trial].
    Hiroo K; Oda T; Kushiyama T; Higashi K; Yamamoto K
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():445-50. PubMed ID: 21661182
    [No Abstract]   [Full Text] [Related]  

  • 4. [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
    Rodríguez Pérez JC; Novoa Novoa J; Caballero A; Anabitarte A; Plaza C; Palop L; Rodríguez Esparragón F
    Nefrologia; 2005; 25(5):500-8. PubMed ID: 16392299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
    Kjeldsen SE; Julius S; Mancia G; McInnes GT; Hua T; Weber MA; Coca A; Ekman S; Girerd X; Jamerson K; Larochelle P; MacDonald TM; Schmieder RE; Schork MA; Stolt P; Viskoper R; Widimský J; Zanchetti A;
    J Hypertens; 2006 Jul; 24(7):1405-12. PubMed ID: 16794491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
    Menne J; Izzo JL; Ito S; Januszewicz A; Katayama S; Chatzykirkou C; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G; Haller H;
    J Hypertens; 2012 Apr; 30(4):811-8; discussion 818. PubMed ID: 22418908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
    Iwashima Y; Okada M; Haneda M; Yoshida T
    Diabetes Res Clin Pract; 2006 Oct; 74(1):8-14. PubMed ID: 16720057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks].
    Praxis (Bern 1994); 2004 Oct; 93(44):1836. PubMed ID: 15559910
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging.
    Ogihara T; Fujimoto A; Nakao K; Saruta T
    J Am Geriatr Soc; 2010 Feb; 58(2):395-6. PubMed ID: 20370872
    [No Abstract]   [Full Text] [Related]  

  • 13. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE; McInnes GT; Mancia G; Hua TA; Julius S; Weber MA; Coca A; Girerd X; Jamerson K; Larochelle P; Macdonald T; Schmieder RE; Anthony Schork M; Viskoper R; Widimsky J; Zanchetti A
    Blood Press; 2008; 17(3):170-7. PubMed ID: 18608200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Control of systolic blood pressure in the VALUE trial after 12 months].
    Schmieder RE; Handrock R;
    Dtsch Med Wochenschr; 2003 Mar; 128(10):485-6. PubMed ID: 12627338
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
    Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
    Saisho Y; Komiya N; Hirose H
    Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).
    Kawamori R; Daida H; Tanaka Y; Miyauchi K; Kitagawa A; Hayashi D; Kishimoto J; Ikeda S; Imai Y; Yamazaki T
    BMC Cardiovasc Disord; 2006 Oct; 6():39. PubMed ID: 17029631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
    Weycker D; Edelsberg J; Vincze G; Kjeldsen SE; Jamerson K; Khan ZM; Oster G
    J Hum Hypertens; 2007 May; 21(5):374-80. PubMed ID: 17314999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.